Navigation Links
Study evaluates risk factors for chronic TMJD
Date:11/10/2011

be so difficult is the chronic pain associated with TMJD results from a highly complex biological interplay. The interplay involves myriad factors, ranging from the intricacies of pain transmission and its possible rewiring and overamplification en route to the brain to the complicating and frequent presence of other painful conditions, such as fibromyalgia and chronic fatigue, which mask or modify the symptoms of the TMJD.

With so many variables, some researchers have suggested that the best scientific entry point to examine TMJD is during its earliest stages, before the full-blown complexity of advanced disease clouds the investigative picture.

This thinking and progress in studying the basic biology of pain led to the launch of OPPERA in September 2005. It marks the first-ever, large prospective (meaning, looking forward in time) clinical study of TMJD and, more broadly, a chronic pain condition.

The OPPERA Study involves four investigative units: University of Florida in Gainesville, directed by Dr. Roger Fillingim; University of Buffalo-SUNY, directed by Dr. Richard Ohrbach; University of Maryland at Baltimore, overseen by Drs. Joel Greenspan and Ronald Dubner; and the University of North Carolina Chapel Hill, directed by Drs. Gary Slade, Eric Blair, Shad Smith, Luda Diatchenko, and William Maixner, who is also OPPERA's program director. Mr. Charles Knott, with the Battelle Memorial Institute in Columbus, Ohio, served as the director of the Data Coordination Center.

Investigators at the four study sites now have completed tracking 3,200 healthy male and female volunteers, ages 18-44, from three to five years. As expected, a subset of approximately 200 volunteers developed their first bout(s) of TMJD, and researchers are currently analyzing the study data to determine the factors associated with the disease's onset.

The publications in the Journal of Pain, however, stem from an associated but distinct baseline study a
'/>"/>

Contact: Bob Kuska
kuskar@nidcr.nih.gov
301-594-7560
NIH/National Institute of Dental and Craniofacial Research
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Groundbreaking study quantifies health costs of climate-change related disasters in the US
2. Wood biofuel could be a competitive industry by 2020: UBC study
3. Einstein study indicates brain plays role in regulating blood sugar in humans
4. Researchers using new technology to study breath for toxins
5. New study uncovers how brain cells degrade dangerous protein aggregates
6. HIV study identifies key cellular defence mechanism
7. UI researcher to study glaucoma in dogs
8. New study suggests EU biofuels are as carbon intensive as petrol
9. BGSU researchers harness power of genome institute for Great Lakes study
10. Albert Einstein College of Medicine receives $8 million from NIH to study how cancer spreads
11. Vegetarian diet, physical activity protect against diabetes in black population, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... A survey of emergency contraceptive pills in Peru ... were either of substandard quality or falsified. Many ... had the wrong active ingredient. One batch had ... detect the fake drugs, researchers at the Georgia ... mass spectrometry to quickly assess suspected counterfeit drugs ...
(Date:4/18/2014)... a twist to the story of how barnyard chickens came ... in the journal Proceedings of the National Academy of ... that lived 200-2300 years ago in Europe, researchers report that ... looked far different from the chickens we know today. , ... with modern domestic chickens -- such as their yellowish skin ...
(Date:4/17/2014)... In the most densely forested and most densely populated ... of human needs, values and practices. Disturbances associated with ... agriculture and development, have set the stage for management ... study reports. , The report Five anthropogenic factors ... in the Northern United States was published ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... S.C., Sept. 17, 2012   Eliza Corporation ("Eliza") , the ... BlueCross BlueShield of South Carolina ("BlueCross") announced ... members increased 45 percent over 2011 rates. In fact, ... exceeded expectations in all areas, and as a result ...
... Research Institute and Sea Lane Biotechnologies have solved the co-crystal ... in a unique way. The antibody recognizes the crucial structure ... though previously this structure had been thought too small for ... hit this precise spot by using just a small part ...
... developed a method that for the first time provides ... and subsequently remove them in a repeatable cycle., Their ... week in the journal Nature Methods , will ... formed proteins in order to create better antibiotics, anti-cancer ...
Cached Biology News:Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 2Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 3Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 4Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies 2Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies 3Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Progression-free Survival with Campath, CAMBRIDGE, Mass. and ... GENZ ) and Bayer HealthCare Pharmaceuticals Inc.,(NYSE: ... and Drug Administration,(FDA) has approved a supplemental biologics ... approval for single-agent,Campath for the treatment of B-cell ...
... LOS ANGELES, Sept. 20 Signalife announced,today that it ... (two,million dollars) of Fidelity 100 units thus far in ... which anticipates additional sales,orders resulting from its current efforts, ... About Signalife: Signalife, Inc. is an award-winning ...
... Inc.,(TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused ... and CEO,David J. Mazzo, Ph.D., will present a Company ... September 27, 2007 at 10:00 a.m.,Eastern, in the Ballroom ... City. A live webcast of this presentation will ...
Cached Biology Technology:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Signalife Achieves $1.98 Million Sales Orders Thus Far 2
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
Biology Products: